 MEI Pharma NASDAQ:MEIP was downgraded by Zacks Investment Research from a strong-buy rating to a hold rating in a research note issued on Friday, Zacks.com reports. According to Zacks, MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development ... 